US pharmaceutical majors are putting pressure on the Indian government to stop issuing permits to domestic companies for the manufacture of low-priced copies of patented life-saving drugs.
According to the international medical humanitarian organisation Medecins Sans Frontieres (MSF), pharma companies are aggressively lobbying the US Congress and the Obama administration in a broad campaign to press India into changing its IP laws. India is a critical producer of affordable medicines, and competition among generic drug manufacturers has brought down the price of medicines for HIV, TB and cancer by more than 90%.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.